Viridian to Webcast VRDN-001 Phase 3 THRIVE Results

Viridian Therapeutics, Inc., a biopharmaceutical firm targeting the development of superior medicines for serious and rare diseases, is set to hold a conference call and webcast to disclose key results from its THRIVE phase 3 clinical trial. This trial evaluates the efficacy of VRDN-001 in treating patients with active Thyroid Eye Disease (TED). The event is scheduled for Tuesday, September 10, 2024, at 8:00 am ET.

Viridian Therapeutics is headquartered in Waltham, Massachusetts. The company's primary focus is on discovering and engineering medications that could be among the best available for patients with severe and rare conditions. Utilizing its proficiency in antibody discovery and protein engineering, Viridian is committed to developing unique therapeutic candidates that target previously validated drug targets within commercially viable disease areas.

The company is currently advancing several candidates aimed at treating patients with TED. A central part of this effort is the clinical development program for VRDN-001, which includes two global phase 3 clinical trials—THRIVE and THRIVE-2. These trials are designed to assess the effectiveness and safety of VRDN-001 in individuals suffering from both active and chronic TED. Additionally, Viridian is progressing with VRDN-003, a potential best-in-class subcutaneous treatment for TED. This treatment is being evaluated through two planned global phase 3 clinical trials named REVEAL-1 and REVEAL-2, which will also assess its efficacy and safety in patients with active and chronic TED.

Beyond its focus on TED, Viridian is exploring a novel range of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008. These inhibitors show promise for development in various autoimmune diseases, broadening the scope of Viridian's therapeutic efforts.

The webcast of the upcoming conference call can be accessed under the "Events and Presentations" section on the Investors segment of the Viridian website. For those wishing to participate in the conference call, domestic participants can dial 800-715-9871, while international participants should dial 646-307-1963 and reference code 8636908. A replay of the webcast will be available after the event concludes, offering further opportunities for interested parties to gain insights into the trial results and the company's future directions.

Viridian Therapeutics continues to focus on advancing its pipeline of potential treatments, driven by a commitment to improving the lives of patients with serious and often overlooked medical conditions. This upcoming conference call and webcast represent a significant milestone in their efforts to bring innovative treatments to market.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!